Prof. Umberto Vespasiani-Gentilucci was born in Rome on February 8th 1978. On July 2002, he graduated in Medicine magna cum laude and, on November 2007, he specialized in Internal Medicine, both at the Campus Bio-Medico University of Rome. On 2012, he became Philosophy Doctor in Experimental and Clinical Hepatology at “La Sapienza” University of Rome. From April 2016 to November 2019 he has been Assistant Professor of Internal Medicine and since November 2019 he is Assistant Professor of Internal Medicine at the Campus Bio-Medico University. From 2007 to 2010 he served as consultant and, since 2010, he is fully employed at the Campus Bio-Medico Hospital. From July 2013 to December 2016 he has been scientific advisor for the Agenzia Italiana del Farmaco (AIFA) and the European Medicines Agency (EMA). He has always been strongly involved in experimental and clinical research mainly in the field of Hepatology and Internal Medicine, and he is Author or co-Author of >150 publications on International journals indexed in Medline. His principal areas of research are fatty liver disease (predictors of progression and new molecular targets), and mechanisms of hepatic fibrogenesis, with a particular focus on the role of intestinal microbiota and the Lypopolysaccharides/Toll-like receptor-4 axis. Most of his research activity is carried on in collaboration with other National and International groups, among which in particular the Division of Hepatology and Gene Therapy at the Center for Applied Medical Research (CIMA) of the University of Navarra, Pamplona (Spain) and the Division of Molecular and Clinical Medicine at the Institute of Medicine of the Sahlgrenska Academy, Gotheborg (Sweden). He is reviewer for several International Journals mainly in the field of Gastroenterology/Hepatology.